The total market size of non-alcoholic steatohepatitis (NASH) is anticipated to upsurge during the forecast period due to the expected entry of emerging therapies that include MGL-3196 (Resmetirom), Lanifibranor/ IVA337, Efruxifermin, and others. LAS VEGAS, Jan. 17, 2024 /PRNewswire/ –…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.